UL-FS 49 (zatebradine) does not affect arterial baroreflex in conscious normal or aortic-constricted rats

Journal of Cardiovascular Pharmacology
M SakamotoE L Yellin

Abstract

Heart-rate reduction is an important element of patient management during cardiac bypass surgery and in therapeutic measures for combating ischemia and relieving pain in patients with angina. UL-FS 49 is a novel bradycardic agent that purportedly acts solely on the sinoatrial node without potentially deleterious effects on arterial pressure and cardiac inotropism. However, little is known about influences of this agent on neuronal tissue and cardiovascular reflexes. Moreover, left ventricular hypertrophy, which often accompanies cardiovascular disease, is known to attenuate the arterial baroreflex and could have effects interactive with those of UL-FS 49. In this study, the effects of UL-FS 49 on the arterial baroreflex were tested in normal rats (N), rats with left ventricular hypertrophy 14 days after abdominal aortic constriction (AC), and sham-operated controls (SH). Arterial baroreflex sensitivity (BRS) was estimated as the slope of the relation between mean arterial pressure (independent variable) and the RR interval (dependent variable). At the time of study, the AC group had significantly greater mean arterial pressure than either SH or N (159 +/- 2, 122 +/- 3, and 124 +/- 3 mm Hg, respectively; mean +/- SEM, p < 0.01) ...Continue Reading

References

Apr 1, 1990·Naunyn-Schmiedeberg's Archives of Pharmacology·T Doerr, W Trautwein
Oct 1, 1991·Journal of Cardiovascular Pharmacology·W E JohnstonW C Little
Dec 1, 1989·Journal of Molecular and Cellular Cardiology·M ChibaH Toshima
Jan 1, 1985·Journal of Cardiovascular Pharmacology·J W DämmgenG J Gross
Oct 1, 1988·The American Journal of Physiology·V Fatigati, M J Peach
Jul 1, 1986·Canadian Journal of Physiology and Pharmacology·F M Siri, R M Smith
Apr 1, 1972·The Journal of Clinical Investigation·C B HigginsE Braunwald
Feb 1, 1970·The American Journal of Physiology·E M Krieger
Apr 1, 1966·Circulation·B M HightowerJ W Kirklin
Jan 1, 1984·European Journal of Clinical Pharmacology·J F GiudicelliA Jacolot
Jul 1, 1995·Journal of Cardiovascular Pharmacology·O PérezJ Tamargo
Jan 1, 1994·Journal of the American College of Cardiology·J C WynsenD C Warltier
Feb 1, 1993·Journal of the American College of Cardiology·J A BreallW Grossman
Mar 1, 1996·Basic Research in Cardiology·K H RyuJ Ross
Sep 27, 1962·The New England Journal of Medicine·C A CHIDSEYE BRAUNWALD
Sep 1, 1965·The American Journal of Medicine·C A CHIDSEYA G MORROW

❮ Previous
Next ❯

Citations

Feb 25, 2003·Life Sciences·Robert L HamlinCynthia A Carnes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.